Stock Research for ACAD

ACAD

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ACAD Stock Chart & Research Data

The ACAD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACAD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ACAD Due diligence Resources & Stock Charts

The ACAD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACAD Detailed Price Forecast - CNN Money CNN View ACAD Detailed Summary - Google Finance
Yahoo View ACAD Detailed Summary - Yahoo! Finance Zacks View ACAD Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ACAD Trends & Analysis - Trade-Ideas Barrons View ACAD Major Holders - Barrons
NASDAQ View ACAD Call Transcripts - NASDAQ Seeking View ACAD Breaking News & Analysis - Seeking Alpha
Spotlight View ACAD Annual Report - CompanySpotlight.com OTC Report View ACAD OTC Short Report - OTCShortReport.com
TradeKing View ACAD Fundamentals - TradeKing Charts View ACAD SEC Filings - Bar Chart
WSJ View Historical Prices for ACAD - The WSJ Morningstar View Performance/Total Return for ACAD - Morningstar
MarketWatch View the Analyst Estimates for ACAD - MarketWatch CNBC View the Earnings History for ACAD - CNBC
StockMarketWatch View the ACAD Earnings - StockMarketWatch MacroAxis View ACAD Buy or Sell Recommendations - MacroAxis
Bullish View the ACAD Bullish Patterns - American Bulls Short Pains View ACAD Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ACAD Stock Mentions - StockTwits PennyStocks View ACAD Stock Mentions - PennyStockTweets
Twitter View ACAD Stock Mentions - Twitter Invest Hub View ACAD Investment Forum News - Investor Hub
Yahoo View ACAD Stock Mentions - Yahoo! Message Board Seeking Alpha View ACAD Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ACAD - SECform4.com Insider Cow View Insider Transactions for ACAD - Insider Cow
CNBC View ACAD Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACAD - OTC Markets
Yahoo View Insider Transactions for ACAD - Yahoo! Finance NASDAQ View Institutional Holdings for ACAD - NASDAQ


Stock Charts

FinViz View ACAD Stock Insight & Charts - FinViz.com StockCharts View ACAD Investment Charts - StockCharts.com
BarChart View ACAD Stock Overview & Charts - BarChart Trading View View ACAD User Generated Charts - Trading View




Latest Financial News for ACAD


INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Posted on Tuesday July 17, 2018

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“ACADIA” or ''the Company'') (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. ACADIA shares fell more than 23% on April 9, 2018, after CNN reported that the Company’s Nuplazid treatment may have played a role in the death of patients receiving the treatment.


EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against ACADIA Pharmaceuticals Inc. – ACAD
Posted on Tuesday July 17, 2018

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of ACADIA Pharmaceuticals Inc. resulting from allegations that ACADIA may have issued materially misleading business information to the investing public.


Glancy Prongay & Murray LLP Continues Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)
Posted on Tuesday July 17, 2018

Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD) investors concerning the Company and its officers’ possible violations of federal securities laws. On April 9, 2018, CNN reported that “[p]hysicians, medical researchers and other experts told CNN that they worried that [Nuplazid] had been approved too quickly, based on too little evidence that it was safe or effective.” On this news, ACADIA’s share price fell more than 23% on April 9, 2018, thereby injuring investors. Then, on April 25, 2018, CNN reported that the U.S. Food and Drug Administration was re-examining the safety of Nuplazid, which was approved “despite concerns that not enough was known about the drug’s risks.” On this news, ACADIA’s share price fell nearly 22% on April 25, 2018, thereby further injuring investors.


INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors
Posted on Monday July 16, 2018

Law Offices of Howard G. Smith continues its investigation on behalf of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company) (NASDAQ: ACAD) investors concerning the Company and its officers’ possible violations of federal securities laws. On April 9, 2018, CNN reported that “[p]hysicians, medical researchers and other experts told CNN that they worried that [Nuplazid] had been approved too quickly, based on too little evidence that it was safe or effective.” On this news, ACADIA’s share price fell more than 23% on April 9, 2018, thereby injuring investors. Then, on April 25, 2018, CNN reported that the U.S. Food and Drug Administration was re-examining the safety of Nuplazid, which was approved “despite concerns that not enough was known about the drug’s risks.” On this news, ACADIA’s share price fell nearly 22% on April 25, 2018, thereby further injuring investors.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.